Acute M1 Myeloid Leukemia

Acute M1 myeloid leukemia is a fast-growing blood and bone-marrow cancer. It starts from very early myeloid stem cells that should become healthy white cells, red cells, and platelets. In M1, the cells are “blasts” with no meaningful maturation. They multiply quickly, crowd the marrow, and spill into the blood. Because normal blood cells are replaced, people develop anemia, infections, and bleeding. Diagnosis is made by blood counts, blood smear, bone-marrow aspiration/biopsy, flow cytometry, cytogenetics, and molecular tests. Treatment needs urgent specialist care and often includes induction chemotherapy, targeted drugs based on mutations, supportive care, and sometimes stem-cell transplant.

Acute M1 myeloid leukemia is a fast-growing blood cancer that starts in the bone marrow—the “factory” that makes blood cells. In AML-M1, very early myeloid cells (called blasts) multiply quickly but do not mature into healthy white cells, red cells, or platelets. Doctors historically used the FAB system (French-American-British) to group AML; M1 means “without significant maturation”: the marrow is packed with myeloblasts and only a small fraction show maturing features. People get tired (anemia), bruise or bleed easily (low platelets), and get infections (low normal white cells). Treatment usually has two parts: induction (to get leukemia into remission) and consolidation/maintenance (to keep it away), sometimes followed by allogeneic stem-cell transplant for cure in appropriate patients. Modern care often adds targeted medicines if specific mutations like FLT3 or IDH1/2 are present. Cancer.gov+1

Other names

Acute M1 myeloid leukemia is also called AML-M1 (FAB classification) and acute myeloblastic leukemia without maturation. In modern WHO/ICC systems, it most closely maps to “AML, NOS — without maturation” when no defining genetic abnormality is present. Older literature may say acute non-lymphocytic leukemia (ANLL) M1. Some reports loosely label it “AML with minimal maturation,” but strictly speaking that term aligns more with FAB M2/WHO “with maturation,” whereas M1 emphasizes little to no maturation of myeloid blasts.

Types

Even though FAB “M1” describes the appearance of the blasts, doctors further classify it by cause and genetics because these guide therapy and prognosis.

• By clinical setting

  • De novo M1 AML: No known preceding blood disorder or chemotherapy/radiation.

  • Secondary M1 AML: Evolves from myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN).

  • Therapy-related M1 AML: Occurs after prior chemo (alkylators, topoisomerase II inhibitors) or radiation.

• By cytogenetics (karyotype)

  • Normal karyotype.

  • Complex karyotype (many chromosomal changes).

  • Specific abnormalities (e.g., monosomy 5/7 or del(5q)/del(7q), trisomy 8). Defining rearrangements like t(8;21), inv(16), or PML-RARA usually place the leukemia outside M1.

• By mutations (molecular profile)

  • FLT3-ITD/TKD, NPM1, CEBPA (biallelic), RUNX1, TP53, IDH1/IDH2, DNMT3A, ASXL1, TET2, etc.
    The exact mutation set strongly influences prognosis and the use of targeted drugs (e.g., FLT3 or IDH inhibitors).

---

Causes

“Causes” in leukemia are usually risk factors that raise the chance of disease; often no single cause is found in one person.

1. Age and DNA wear
   With age, marrow stem cells collect DNA errors. Some errors drive leukemia growth. That is why AML risk rises in older adults.

2. Clonal hematopoiesis (CHIP)
   Healthy people can acquire mutations (DNMT3A, TET2, ASXL1). Most never get AML, but CHIP raises future AML risk, especially if additional hits occur.

3. Prior chemotherapy (alkylating agents)
   Past treatment for another cancer with alkylators (e.g., cyclophosphamide) can injure marrow DNA, leading years later to therapy-related AML.

4. Topoisomerase II inhibitors
   Drugs like etoposide can cause specific DNA breaks and rearrangements, producing AML that may appear within a few years.

5. Radiation exposure
   High-dose therapeutic or accidental radiation damages marrow stem-cell DNA and increases AML risk.

6. Benzene and solvent exposure
   Chronic exposure to benzene (industry, fuel) is a classic environmental risk for AML due to marrow toxicity and DNA damage.

7. Smoking
   Tobacco smoke contains benzene and other carcinogens; long-term smoking increases AML risk.

8. Pre-existing MDS (myelodysplastic syndrome)
   MDS can progress to AML when the abnormal clone gains new mutations and outgrows normal cells.

9. Myeloproliferative neoplasms (MPN)
   Diseases like polycythemia vera or myelofibrosis can transform into AML after years of clonal evolution.

10. Aplastic anemia (post-therapy evolution)
    Rarely, long-standing aplasia or treatment can lead to clonal changes and AML.

11. Paroxysmal nocturnal hemoglobinuria (PNH)
    A PNH clone may coexist with marrow failure; clonal evolution in this setting can rarely produce AML.

12. Congenital Down syndrome
    Children with trisomy 21 have higher AML risk. Specific AML subtypes are more typical, but general risk is still increased.

13. Fanconi anemia
    Inherited DNA-repair defects cause chromosomal breaks and a high risk of AML at young ages.

14. Bloom syndrome, ataxia-telangiectasia, Nijmegen breakage syndrome
    All impair DNA repair or checkpoint control, increasing leukemia susceptibility.

15. Li-Fraumeni syndrome (TP53)
    A germline TP53 mutation leads to multiple cancers, including AML, due to weak tumor-suppressor control.

16. Neurofibromatosis type 1 (NF1)
    RAS-pathway dysregulation elevates risk for several hematologic malignancies.

17. Noonan syndrome
    Germline RAS-pathway variants can predispose to myeloid diseases, especially in childhood.

18. Familial platelet disorder with RUNX1 mutation
    This hereditary condition carries a significant lifetime risk of AML.

19. GATA2 deficiency
    Germline GATA2 mutations cause immunodeficiency and a strong predisposition to MDS/AML.

20. Obesity and chronic inflammation
    Metabolic and inflammatory stress may promote clonal expansion and mutational selection, modestly raising AML risk.

---

Symptoms and signs

1. Fatigue and weakness
   Too few red cells (anemia) means less oxygen delivery to muscles and brain, so everyday tasks feel exhausting.

2. Shortness of breath on exertion
   Anemia makes the heart and lungs work harder, so climbing stairs or walking far causes breathlessness.

3. Pale skin (pallor)
   Low hemoglobin gives a washed-out appearance of the skin and inner eyelids.

4. Frequent infections or slow recovery
   Low healthy neutrophils and dysfunctional blasts weaken the immune response, so infections occur often and last longer.

5. Fever (with or without infection)
   Fevers can reflect infection or inflammatory signals released by leukemia cells.

6. Easy bruising and petechiae
   Low platelets (thrombocytopenia) cause pinpoint red spots and large bruises after minor bumps.

7. Bleeding gums or nosebleeds
   Platelet shortage and fragile vessel lining lead to mucosal bleeding.

8. Prolonged bleeding from cuts
   Clotting is slow because platelets and coagulation balance are disturbed.

9. Bone or joint pain
   A packed marrow stretches the bone lining and can cause deep, aching pain or tenderness.

10. Weight loss and poor appetite
    Cancer-related inflammation and high cell turnover reduce appetite and increase energy use.

11. Night sweats
    Cytokines from leukemia cells can reset temperature control, causing drenching sweats.

12. Enlarged spleen or liver (fullness, early satiety)
    Organs that filter blood may swell with leukemia cells, making the abdomen feel full.

13. Swollen lymph nodes (sometimes)
    Less common than in lymphoid cancers, but nodes can enlarge if blasts accumulate.

14. Headache, confusion, vision changes
    Very high white counts can thicken blood (leukostasis), reducing oxygen delivery to the brain or eyes.

15. Skin changes (leukemia cutis—uncommon in M1)
    Painless purple-brown bumps or plaques can appear if cells infiltrate the skin (more typical in some monocytic subtypes, but possible).

---

Diagnostic tests

A) Physical exam

1. Vital signs and general look
   Temperature, heart rate, blood pressure, and breathing rate show infection, sepsis risk, anemia strain, or dehydration.

2. Skin, nail beds, and mouth inspection
   Pallor, petechiae, bruises, gum bleeding, or mouth sores point to anemia, low platelets, and infection risk.

3. Lymph node check
   Neck, armpit, and groin nodes are palpated. Big, firm nodes suggest infiltration or infection.

4. Abdomen exam for spleen/liver
   Doctors feel under the ribs. An enlarged spleen or liver supports a leukemia diagnosis or shows disease burden.

5. Neurologic and eye exam
   A focused exam looks for confusion, weakness, retinal hemorrhages, or papilledema when counts are very high.

B) “Manual” tests

6. Manual differential count on blood smear
   A technologist counts 100–200 cells by hand, estimating the percentage of blasts and other cells. It helps flag AML even before marrow tests return.

7. Manual platelet estimate on smear
   Counting platelets per high-power field confirms severe thrombocytopenia when automated counters are unreliable.

8. Manual reticulocyte count
   This measures young red cells. A low reticulocyte count with anemia suggests the marrow is failing due to leukemia.

C) Laboratory & pathological tests

9. Complete blood count (CBC) with automated differential
   Shows anemia, low platelets, abnormal or very high white counts, and flags blasts. It is the first lab clue to AML.

10. Peripheral blood smear review
    A pathologist examines cell shape and granules. In M1, blasts dominate and show little maturation; Auer rods may be present.

11. Bone-marrow aspiration and core biopsy
    This is the definitive test. It estimates blast percentage (≥20% blasts supports AML), architecture, and fibrosis, and provides material for all downstream studies.

12. Cytochemical stains (e.g., myeloperoxidase, Sudan Black B)
    These stains highlight myeloid lineage. In M1, blasts are typically myeloperoxidase-positive, confirming myeloid origin.

13. Flow cytometry immunophenotyping
    Antibody panels define surface markers. M1 blasts commonly express myeloid antigens (CD13, CD33, MPO), often stem markers (CD34, HLA-DR), and lack strong B/T-cell markers. This distinguishes AML from ALL.

14. Conventional cytogenetics (karyotype) and FISH
    Chromosome studies detect gains/losses and rearrangements. They place disease into risk groups and can exclude genetic-defined AML entities that trump FAB labels.

15. Molecular mutation panel (NGS/PCR)
    Tests genes such as FLT3, NPM1, CEBPA, RUNX1, IDH1/2, TP53, DNMT3A, ASXL1, TET2. Results guide risk and targeted therapy choices (e.g., FLT3 or IDH inhibitors).

D) Electrodiagnostic tests

16. 12-lead electrocardiogram (ECG)
    Provides a baseline before anthracycline therapy, checks for arrhythmias, ischemia, or QT issues, and helps manage electrolyte disturbances during induction.

17. Continuous pulse oximetry (electronic monitoring)
    Tracks oxygen saturation in patients with anemia, infection, or suspected leukostasis to catch hypoxemia early.

E) Imaging tests

18. Chest X-ray
    Screens for pneumonia, fluid overload, or leukostasis-related changes, which can rapidly complicate AML care.

19. Echocardiogram (heart ultrasound)
    Assesses heart squeeze (ejection fraction) before anthracycline chemotherapy and monitors for chemo-related cardiotoxicity.

20. CT or MRI brain (if symptoms)
    Used for severe headaches, confusion, or neurologic deficits to evaluate hemorrhage, stroke, or leukostasis effects.

Non-pharmacological treatments

(Includes 15 physiotherapy items + mind-body/education supports. Each lists Description (~100–150 words), Purpose, Mechanism, Benefits.)

1. Energy-conserving activity pacing (Physiotherapy)
   Description: Plan your day into short activity bursts with rest periods. Prioritize tasks, sit instead of stand, and use tools (trolley, shower chair).
   Purpose: Reduce fatigue during and after chemo.
   Mechanism: Matches energy supply to demand, limiting lactic build-up and post-exertional crashes.
   Benefits: Better stamina for daily tasks; fewer “bad days.”

2. Graded aerobic walking (Physiotherapy)
   Description: Start with 5–10 minutes at easy pace on “good” days, progressing by 1–2 minutes as tolerated, keeping heart rate modest and stopping for dizziness or fever.
   Purpose: Maintain cardiovascular fitness and mood.
   Mechanism: Mild aerobic work supports mitochondrial efficiency and combats deconditioning.
   Benefits: Less breathlessness, better sleep, improved appetite.

3. Breathing exercises & incentive spirometry (Physiotherapy)
   Description: Slow diaphragmatic breathing and 10 incentive-spirometer breaths each waking hour while admitted.
   Purpose: Prevent pneumonia/atelectasis in immunocompromised patients.
   Mechanism: Expands lung bases and clears secretions.
   Benefits: Fewer chest infections; easier cough.

4. Lower-limb strengthening with bands (Physiotherapy)
   Description: Chair squats, ankle pumps, seated marches with light bands 3–4x/week.
   Purpose: Preserve muscle mass during hospitalization.
   Mechanism: Progressive resistance counters catabolism.
   Benefits: Better mobility, fall risk reduction.

5. Gentle flexibility & joint range (Physiotherapy)
   Description: Daily neck, shoulder, hip, and hamstring stretches (~5–10 minutes).
   Purpose: Offset bed rest stiffness and infusion-line guarding.
   Mechanism: Lengthens shortened tissues; improves synovial flow.
   Benefits: Less pain, easier self-care.

6. Balance & fall-prevention drills (Physiotherapy)
   Description: Heel-to-toe stands near support, sit-to-stand practice, safe footwear education.
   Purpose: Prevent injury when platelets are low.
   Mechanism: Trains proprioception and functional transitions.
   Benefits: Fewer falls, safer discharge home.

7. Edema management & gentle circulation (Physiotherapy)
   Description: Leg elevation, ankle pumps, compression if approved.
   Purpose: Reduce swelling from inactivity or IV fluids.
   Mechanism: Improves venous/lymphatic return.
   Benefits: Comfort, easier walking.

8. Posture & neck/shoulder care (Physiotherapy)
   Description: Scapular retraction drills, ergonomic pillow setup with lines/ports.
   Purpose: Lessen infusion-related neck/shoulder strain.
   Mechanism: Recruits postural muscles; reduces trigger points.
   Benefits: Fewer tension headaches and upper-back aches.

9. Mucositis self-care education (Physiotherapy adjunct)
   Description: Ice chips during certain chemo, bland rinses (salt/baking soda), soft toothbrush technique.
   Purpose: Reduce mouth sores’ pain and infection risk.
   Mechanism: Local cooling and gentle hygiene protect mucosa.
   Benefits: Less pain; easier nutrition.

10. Fatigue self-monitoring with exertion diaries (Physiotherapy/education)
    Description: Track steps, sleep, and symptom spikes to tailor activity.
    Purpose: Personalize pacing.
    Mechanism: Biofeedback helps prevent overexertion.
    Benefits: More consistent energy.

11. Lymphedema/venous clot prevention moves (Physiotherapy)
    Description: Calf pumps, walking laps, avoiding prolonged bed time if counts and vitals allow.
    Purpose: Reduce clots/edema.
    Mechanism: Muscle pump improves flow.
    Benefits: Safer hospitalization.

12. Respiratory hygiene & airway clearance (Physiotherapy)
    Description: Huff cough technique, hydration, and steam inhalation as advised.
    Purpose: Minimize chest infections.
    Mechanism: Mobilizes secretions.
    Benefits: Easier breathing, fewer antibiotics.

13. Gentle yoga or tai chi (Physiotherapy/mind-body)
    Description: 10–20 minutes of slow, supervised movement on stable days.
    Purpose: Reduce stress, maintain flexibility.
    Mechanism: Low-intensity movement + breath regulation.
    Benefits: Mood and sleep gains.

14. Pelvic floor & core stability (Physiotherapy)
    Description: Basic core bracing and pelvic floor squeezes.
    Purpose: Maintain trunk control for safe mobility.
    Mechanism: Trains deep stabilizers.
    Benefits: Easier transfers, less back pain.

15. Peripheral neuropathy foot care education (Physiotherapy/education)
    Description: Inspect feet daily, cushioned shoes, report tingling or numbness early.
    Purpose: Prevent falls and wounds.
    Mechanism: Hazard reduction + early reporting.
    Benefits: Fewer complications.

16. Mindfulness-based stress reduction (Mind-body)
    Description: 10 minutes/day guided breath/body scan.
    Purpose: Lower anxiety and pain perception.
    Mechanism: Calms sympathetic overdrive; improves coping.
    Benefits: Better sleep, less distress.

17. Brief cognitive-behavioral coping (Mind-body)
    Description: Identify unhelpful thoughts (“I’m helpless”) and replace with practical plans (“I can control…meals, walks, masks”).
    Purpose: Reduce depression/anxiety.
    Mechanism: Cognitive reframing.
    Benefits: More adherence to care.

18. Peer support & family communication coaching (Educational therapy)
    Description: Short, structured check-ins with a counselor/support group.
    Purpose: Reduce isolation, share tips.
    Mechanism: Social learning and normalization.
    Benefits: Hope and practical problem-solving.

19. Infection-prevention skills (Educational therapy)
    Description: Hand hygiene, mask use, door-handle habits, visitors screening, food safety (cook meats, avoid raw eggs/sushi, use pasteurized dairy).
    Purpose: Lower infection risk during neutropenia.
    Mechanism: Reduces pathogen exposure.
    Benefits: Fewer fevers and admissions. CDCOncolink

20. Neutropenic-safe food handling (Educational therapy)
    Description: Wash produce well; avoid buffets; reheat deli meats; keep cold foods cold. Strict “no fresh produce” diets are not universally recommended—focus on safe handling per your center.
    Purpose: Balance safety and nutrition.
    Mechanism: Cuts food-borne risk without unnecessary restriction.
    Benefits: Adequate calories with safety. ASCO PublicationsMemorial Sloan Kettering Cancer Center

21. Sleep hygiene routine (Mind-body)
    Description: Same bedtime, screen curfew, relaxation audio.
    Purpose: Improve recovery and mood.
    Mechanism: Circadian alignment.
    Benefits: Energy and immune support.

22. Symptom trigger logging (Educational therapy)
    Description: Record what precedes fever, nausea, mouth sores.
    Purpose: Earlier reporting and prevention.
    Mechanism: Pattern recognition.
    Benefits: Faster interventions.

23. Goal-setting & return-to-roles plan (Educational therapy)
    Description: Small weekly goals (e.g., two short walks, call a friend).
    Purpose: Maintain identity and motivation.
    Mechanism: Behavioral activation.
    Benefits: Less demoralization.

24. Financial/toxic stress navigation (Educational therapy)
    Description: Meet social worker early to map coverage and travel help.
    Purpose: Reduce stress that worsens symptoms.
    Mechanism: Resource linkage.
    Benefits: Better adherence.

25. Clinical trials literacy (Educational therapy)
    Description: Learn basics of trial phases and how they differ from routine care.
    Purpose: Informed choices if eligible.
    Mechanism: Education empowers consent.
    Benefits: Access to novel options. Cancer.gov

---

Drug treatments

Safety note: Doses and schedules vary by age, kidney/liver function, genetics, and local protocols. Only your oncology team can prescribe safely.

1. Cytarabine (antimetabolite, backbone of “7+3”)
   Purpose: Kill leukemic blasts during induction/consolidation.
   Mechanism: Cytidine analog; gets incorporated into DNA and halts replication.
   Dose/Time (typical): In “7+3,” continuous IV infusion for 7 days; high-dose IV used in consolidation.
   Side effects: Low blood counts, mucositis, liver enzyme rise, cerebellar toxicity at high doses (unsteady gait), conjunctivitis (prevented with steroid eye drops). Cancer.gov

2. Daunorubicin (anthracycline, “7+3”)
   Purpose: Synergize with cytarabine in induction.
   Mechanism: Intercalates DNA; topoisomerase II inhibition; free radicals.
   Dose/Time: IV days 1–3 in induction (dose per protocol).
   Side effects: Neutropenia, nausea, hair loss, mucositis; cardiotoxicity (baseline/periodic heart assessment). Cancer.gov

3. Idarubicin (anthracycline alternative)
   Purpose: Alternative to daunorubicin in “7+3.”
   Mechanism: Anthracycline class; topo II inhibition.
   Dose/Time: IV days 1–3; protocol-specific.
   Side effects: Similar to daunorubicin; cardiotoxicity risk. Cancer.gov

4. CPX-351 (liposomal daunorubicin + cytarabine; Vyxeos)
   Purpose: First-line for therapy-related AML or AML with myelodysplasia-related changes.
   Mechanism: Fixed 5:1 molar ratio liposomes deliver synergistic combo to blasts.
   Dose/Time: IV on specific days in induction and consolidation per label.
   Side effects: Prolonged cytopenias, infection risk, nausea; cardiac monitoring still required. Indication is specific to t-AML/AML-MRC. U.S. Food and Drug AdministrationPubMed

5. Midostaurin (FLT3 inhibitor)
   Purpose: Add to induction/consolidation for FLT3-mutated AML.
   Mechanism: Multikinase inhibitor targeting FLT3; reduces FLT3-driven proliferation.
   Dose/Time: 50 mg orally twice daily with food on days 8–21 of each induction and consolidation cycle; may continue maintenance per label.
   Side effects: Nausea, rash, cytopenias; QT prolongation—ECG/electrolytes monitoring. U.S. Food and Drug Administration

6. Quizartinib (Vanflyta; FLT3-ITD inhibitor)
   Purpose: For newly diagnosed FLT3-ITD–positive AML with standard chemo and as post-chemo maintenance (no transplant).
   Mechanism: Selective FLT3 inhibitor.
   Dose/Time: Oral; dosing per label across induction, consolidation, and maintenance.
   Side effects: Cytopenias, QT prolongation; ECG checks. U.S. Food and Drug AdministrationCancer.gov

7. Gilteritinib (Xospata; FLT3 inhibitor)
   Purpose: Relapsed/refractory FLT3-mutated AML.
   Mechanism: Inhibits FLT3 signaling to stop leukemic growth.
   Dose/Time: Oral daily; dose per label until progression/toxicity.
   Side effects: Elevated LFTs, differentiation syndrome, QT prolongation; ECG and labs. Cancer.gov

8. Venetoclax (BCL-2 inhibitor)
   Purpose: For newly diagnosed older/unfit adults in combination with azacitidine, decitabine, or low-dose cytarabine; also used widely in practice for R/R settings per trials.
   Mechanism: Blocks BCL-2, priming blasts for apoptosis.
   Dose/Time: Oral with a ramp-up to reduce tumor lysis; daily in 28-day cycles combined with HMA/LDAC.
   Side effects: Profound neutropenia, infections, tumor lysis risk; careful prophylaxis and dose holds are common. U.S. Food and Drug Administration+1PMC

9. Azacitidine (hypomethylating agent)
   Purpose: With venetoclax for older/unfit patients; also used as maintenance (oral azacitidine “Onureg” in first remission in select cases).
   Mechanism: DNA hypomethylation reactivates tumor suppressor genes; cytotoxic at higher doses.
   Dose/Time: SC/IV 7-day cycles; oral azacitidine is a distinct maintenance formulation.
   Side effects: Cytopenias, GI upset; monitor counts. Cancer.gov

10. Decitabine (hypomethylating agent)
    Purpose: Alternative to azacitidine in combo with venetoclax for older/unfit AML.
    Mechanism: DNA methyltransferase inhibition.
    Dose/Time: IV over 5–10 days per cycle.
    Side effects: Neutropenia, infection risk. U.S. Food and Drug Administration

11. Gemtuzumab ozogamicin (anti-CD33 antibody–drug conjugate)
    Purpose: For CD33-positive AML in newly diagnosed and relapsed/refractory settings (selected patients).
    Mechanism: Antibody binds CD33 and delivers calicheamicin toxin inside blasts.
    Dose/Time: Fractionated IV doses per label, sometimes added to chemo in favorable-risk AML.
    Side effects: Myelosuppression, infusion reactions, sinusoidal obstruction syndrome (liver)—careful transplant planning. U.S. Food and Drug AdministrationPubMed

12. Ivosidenib (IDH1 inhibitor)
    Purpose: For IDH1-mutated AML—newly diagnosed older/unfit (often with azacitidine) and relapsed/refractory.
    Mechanism: Blocks mutant IDH1, lowering 2-hydroxyglutarate and allowing normal differentiation.
    Dose/Time: Oral daily; combination schedules per label.
    Side effects: Differentiation syndrome (fever, lung issues), QT prolongation; close monitoring. U.S. Food and Drug AdministrationPubMed

13. Olutasidenib (IDH1 inhibitor)
    Purpose: Relapsed/refractory IDH1-mutated AML; emerging maintenance research.
    Mechanism: Inhibits mutant IDH1, promoting differentiation.
    Dose/Time: Oral; dosing per 2022 label.
    Side effects: Differentiation syndrome, liver enzyme elevations; ECG/labs as directed. U.S. Food and Drug AdministrationFDA Access Data

14. Enasidenib (IDH2 inhibitor)
    Purpose: Relapsed/refractory IDH2-mutated AML.
    Mechanism: Lowers oncometabolite 2-HG; induces differentiation.
    Dose/Time: Oral daily; response may take weeks—watch for differentiation syndrome.
    Side effects: Hyperbilirubinemia, leukocytosis, differentiation syndrome; ECG/labs. U.S. Food and Drug AdministrationFDA Access Data

15. Glasdegib (SMO inhibitor) with low-dose cytarabine
    Purpose: For newly diagnosed older/unfit AML in combination with LDAC.
    Mechanism: Hedgehog pathway inhibition; targets leukemic stem-cell niche signaling.
    Dose/Time: Oral daily; cycles with LDAC.
    Side effects: Cytopenias, dysgeusia, muscle spasms; ECG for QT with interacting drugs. Cancer.gov

Dietary molecular supplements

Important: No supplement cures AML. Use only with oncology approval to avoid drug interactions (e.g., grapefruit/pomegranate can raise levels of venetoclax, midostaurin, and other CYP3A4-metabolized drugs).

1. Vitamin D (if deficient) – supports bone and immune health; typical repletion per labs.

2. Calcium (if intake low) – bone support during steroids/immobility.

3. Vitamin B12 (if low) – corrects deficiency-related anemia/neuropathy.

4. Folate (if low; avoid megadoses without guidance) – supports red-cell production.

5. General multivitamin at RDA – insurance against poor intake.

6. Omega-3 fatty acids – may help appetite/inflammation; watch bleeding risk with thrombocytopenia.

7. Oral glutamine (for mucositis in HSCT settings) – mixed evidence; ask your team.

8. Zinc (if deficient) – wound and taste support; avoid excess.

9. Protein supplements (whey/plant) – meet calorie/protein goals when appetite is low.

10. Ginger (nausea relief) – small amounts in tea/capsules may help; check for interactions with anticoagulants.
    (Use the safe-food rules during neutropenia: wash produce well, cook meats/eggs thoroughly, avoid unpasteurized dairy and buffets.) CDCOncolink

---

Immunity-booster / regenerative / stem-cell–related” drugs or biologics

These do not treat AML directly (except transplant strategies) but support recovery or enable curative procedures. Always oncology-directed.

1. Filgrastim (G-CSF) – stimulates neutrophil production to shorten neutropenia after chemo.

2. Pegfilgrastim (long-acting G-CSF) – same purpose with once-per-cycle dosing.

3. Sargramostim (GM-CSF) – broader myeloid stimulation; sometimes post-transplant.

4. Epoetin alfa/Darbepoetin (ESAs) – red-cell support in select anemia scenarios; not during curative induction unless directed.

5. IVIG (immunoglobulin) – for recurrent severe infections with documented hypogammaglobulinemia; transplant settings.

6. Plerixafor + G-CSF (stem-cell mobilization) – mainly for autologous collection; allogeneic transplant donor mobilization often with G-CSF alone.
   (For many with AML-M1, the definitive “regenerative” approach is allogeneic stem-cell transplant, described below.)

---

Procedures/surgeries

1. Allogeneic hematopoietic stem-cell transplant (HSCT)
   Procedure: After conditioning chemo (± radiation), donor stem cells are infused to rebuild the marrow.
   Why: Offers the highest chance of cure for suitable risk profiles after remission.

2. Leukapheresis
   Procedure: A machine rapidly removes circulating blasts from blood.
   Why: Short-term control of very high white counts to reduce stroke/lung risks while chemo starts.

3. Central venous catheter/port placement
   Procedure: Minor surgical placement of a tunneled line or port.
   Why: Safe, repeated chemo, transfusions, and blood draws.

4. Lumbar puncture ± intrathecal chemo (with possible reservoir)
   Procedure: Needle into spinal fluid to check for leukemia and deliver medicines.
   Why: CNS evaluation/treatment in selected cases.

5. Splenectomy (rare)
   Procedure: Surgical removal of the spleen.
   Why: Considered only for severe symptomatic hypersplenism (pain, transfusion needs) unresponsive to other measures.

---

Prevention & risk-reduction pointers

1. Don’t smoke; avoid second-hand smoke.

2. Occupational safety: minimize benzene/solvent exposure; use PPE.

3. Avoid unnecessary radiation/CT exposure.

4. Manage prior blood disorders (e.g., MDS) under specialist care.

5. Genetic counseling if strong family clustering of hematologic cancers.

6. Vaccinations (flu, COVID, pneumococcal) per oncology timing.

7. Food safety and hand hygiene during treatment. CDC

8. Sun-smart, skin care to protect fragile skin during cytopenias.

9. Medication review to avoid CYP3A4 interactions (e.g., grapefruit, certain herbals).

10. Early symptom reporting (fever ≥38.0°C/100.4°F, bleeding, chest pain).

---

When to see a doctor urgently

• Fever ≥38.0°C (100.4°F), chills, or shaking.

• Bleeding (nose/gums), pinpoint spots (petechiae), or large bruises.

• Shortness of breath, chest pain, confusion, sudden severe headache.

• Painful mouth sores with inability to drink.

• Urinary burning, persistent diarrhea, or new rash.

• Any fall—especially if platelets are low.

• Exposure to someone with a contagious illness while neutropenic. (Neutropenia often occurs 7–12 days after chemo starts; ask your team about your “low-count window.”) CDC

---

What to eat and what to avoid

1. Choose well-cooked proteins (chicken, fish, eggs cooked through).

2. Prefer pasteurized dairy; skip unpasteurized cheeses.

3. Wash fruits/vegetables well; peel when possible; avoid salad bars/buffets.

4. Reheat deli meats until steaming; avoid cold cured meats unless heated.

5. Hydrate with safe, boiled/filtered or bottled water.

6. Small, frequent meals if appetite is low; include protein with each snack.

7. Avoid raw sushi, runny eggs, and sprouts while counts are low.

8. Limit alcohol; avoid if platelets low or on interacting meds.

9. Avoid grapefruit/pomegranate and check for herbal interactions (e.g., St. John’s wort) with targeted drugs.

10. Follow your center’s guidance—many now emphasize food safety over blanket bans on all fresh produce. CDCMD Anderson Cancer CenterASCO Publications

---

FAQs

1) Is AML-M1 different from other AML types?
Yes. AML-M1 (FAB system) means “without maturation”—many blasts, few maturing cells. Treatment today is guided more by genetic mutations (FLT3, IDH1/2, etc.) than by FAB label. Cancer.gov

2) What are the main treatment phases?
Induction to reach remission, then consolidation (± maintenance or transplant) to keep it away. Cancer.gov

3) When is transplant considered?
Often for intermediate/poor-risk genetics after remission, if a donor and fitness allow, to maximize cure chance. Cancer.gov

4) What targeted drugs might I receive?
FLT3 inhibitors (midostaurin, quizartinib; gilteritinib if relapse) or IDH inhibitors (ivosidenib, enasidenib, olutasidenib) if your leukemia has those mutations. U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4U.S. Food and Drug Administration+4Cancer.gov

5) I’m older or not fit for intensive chemo—what are options?
Venetoclax + azacitidine/decitabine/LDAC is a standard path with careful infection prevention. U.S. Food and Drug Administration

6) What is CPX-351 and who gets it?
A liposomal daunorubicin/cytarabine approved for therapy-related AML or AML-MRC. U.S. Food and Drug Administration

7) Why so many ECGs?
Several targeted drugs can prolong QT (e.g., FLT3/IDH inhibitors); ECGs keep therapy safe. U.S. Food and Drug Administration+2U.S. Food and Drug Administration+2

8) Will I lose my hair?
Common with anthracyclines and cytarabine; less so with some targeted agents. Scalp-cooling may not be suitable during AML induction.

9) How are infections prevented?
Hand hygiene, masks during surges, safe food practices, prompt antibiotics for fever, and growth factors in selected settings. CDC

10) Do I need a “neutropenic diet”?
Most centers now stress food safety rather than banning all fresh produce; follow your clinic’s policy. ASCO Publications

11) Can supplements help?
Only to correct deficiencies and only with your team’s approval to avoid interactions.

12) What if my AML comes back?
Options include different chemo, targeted drugs (e.g., gilteritinib for FLT3), venetoclax-based regimens, trials, and transplant evaluation. Cancer.gov

13) How are decisions personalized?
By performance status, organ function, and leukemia genetics (e.g., FLT3, IDH1/2). Molecular testing is standard. Cancer.gov

14) How soon do side effects happen?
Neutropenia typically occurs 7–12 days after chemo starts—know your low-count window. CDC

15) Where can I read authoritative overviews?
The NCI PDQ pages for patients and professionals provide excellent, updated summaries. Cancer.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.